FY2025 Earnings Forecast for Evotec Issued By HC Wainwright

Evotec AG (NASDAQ:EVO) – Stock analysts at HC Wainwright cut their FY2025 EPS estimates for Evotec in a report released on Thursday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.69) per share for the year, down from their previous estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec’s Q4 2025 earnings at $0.07 EPS, Q1 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.65 EPS, FY2028 earnings at $0.79 EPS and FY2029 earnings at $1.07 EPS.

Several other equities analysts have also recently weighed in on EVO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evotec in a research report on Wednesday, November 5th. Royal Bank Of Canada restated an “outperform” rating on shares of Evotec in a research report on Wednesday, September 3rd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.00.

Evotec Trading Down 2.9%

NASDAQ EVO opened at $2.99 on Monday. Evotec has a 52 week low of $2.84 and a 52 week high of $5.64. The business has a 50 day moving average price of $3.73 and a 200-day moving average price of $3.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.49 and a current ratio of 1.58.

Institutional Trading of Evotec

Institutional investors and hedge funds have recently made changes to their positions in the stock. DCF Advisers LLC lifted its position in Evotec by 227.0% in the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company’s stock worth $2,510,000 after buying an additional 521,708 shares during the last quarter. WCM Investment Management LLC bought a new stake in shares of Evotec in the 2nd quarter worth approximately $1,239,000. Pitcairn Co. purchased a new position in Evotec during the 2nd quarter valued at $1,097,000. ABC Arbitrage SA increased its position in shares of Evotec by 239.0% during the third quarter. ABC Arbitrage SA now owns 132,057 shares of the company’s stock valued at $479,000 after buying an additional 93,097 shares during the period. Finally, Envestnet Asset Management Inc. bought a new position in shares of Evotec in the 2nd quarter worth approximately $385,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.